In a subpopulation analysis of the annualized exacerbation rate, the primary outcome of the study, the benefit from tezepelumab, was independent of baseline blood eosinophil counts, a finding that suggests that this anti-TSLP antibody may also be effective for T2-low asthma. Here, TSLP is linked to asthma.